CAT

862.14

+0.47%↑

285.2

+0.12%↑

GEV.US

1,003.71

+0.95%↑

RTX

175.33

+0.08%↑

215.2

-1.31%↓

CAT

862.14

+0.47%↑

285.2

+0.12%↑

GEV.US

1,003.71

+0.95%↑

RTX

175.33

+0.08%↑

215.2

-1.31%↓

CAT

862.14

+0.47%↑

285.2

+0.12%↑

GEV.US

1,003.71

+0.95%↑

RTX

175.33

+0.08%↑

215.2

-1.31%↓

CAT

862.14

+0.47%↑

285.2

+0.12%↑

GEV.US

1,003.71

+0.95%↑

RTX

175.33

+0.08%↑

215.2

-1.31%↓

CAT

862.14

+0.47%↑

285.2

+0.12%↑

GEV.US

1,003.71

+0.95%↑

RTX

175.33

+0.08%↑

215.2

-1.31%↓

Home・Listă Acțiuni・Ocugen Inc

Ocugen Inc

Deschisă

1.3 -1.52

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.28

Maxim

1.34

Indicatori cheie
By Trading Economics
Venit	-1.5M -19M
Vânzări	1.7M 1.5M
EPS	-0.06
Marjă de profit	-1,250.946
Angajați	116
EBITDA	-987K -17M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+732.37% upside

Dividende
By Dow Jones
Următoarele câștiguri	31 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-125M 501M
Deschiderea anterioară	2.82
Închiderea anterioară	1.3

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

0.6818 / 0.74 Suport & Rezistență

Ocugen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 mai 2026, 23:10 UTC

Acțiuni populare

Stocks to Watch: Agilysys, XP

18 mai 2026, 18:44 UTC

Principalele dinamici ale pieței

Claritev Shares Recover After Comments About DOJ

18 mai 2026, 23:55 UTC

Câștiguri

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mai 2026, 23:37 UTC

Market Talk

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mai 2026, 22:31 UTC

Achiziții, Fuziuni, Preluări

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mai 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mai 2026, 22:30 UTC

Achiziții, Fuziuni, Preluări

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mai 2026, 22:25 UTC

Achiziții, Fuziuni, Preluări

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mai 2026, 22:24 UTC

Achiziții, Fuziuni, Preluări

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 mai 2026, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Financial Services Roundup: Market Talk

18 mai 2026, 20:25 UTC

Câștiguri

Correct: XP 1Q Total Client Assets BRL1.53T

18 mai 2026, 20:23 UTC

Câștiguri

XP 1Q Total Client Assets BRL1.53B

18 mai 2026, 20:19 UTC

Câștiguri

XP 1Q Adj EPS BRL2.49 >XP

18 mai 2026, 20:19 UTC

Câștiguri

XP 1Q Rev BRL4.73B >XP

18 mai 2026, 19:10 UTC

Market Talk

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mai 2026, 19:00 UTC

Câștiguri

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mai 2026, 18:52 UTC

Market Talk

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mai 2026, 18:17 UTC

Market Talk

Achiziții, Fuziuni, Preluări

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mai 2026, 17:22 UTC

Market Talk

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mai 2026, 16:57 UTC

Achiziții, Fuziuni, Preluări

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mai 2026, 16:57 UTC

Market Talk

Global Energy Roundup: Market Talk

18 mai 2026, 16:57 UTC

Market Talk

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mai 2026, 16:54 UTC

Achiziții, Fuziuni, Preluări

Vinci Doesn't Set Out Financial Details of Deal

18 mai 2026, 16:50 UTC

Achiziții, Fuziuni, Preluări

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mai 2026, 16:49 UTC

Achiziții, Fuziuni, Preluări

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mai 2026, 16:49 UTC

Achiziții, Fuziuni, Preluări

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mai 2026, 16:48 UTC

Achiziții, Fuziuni, Preluări

Vinci Buys Canada's Modern Group of Companies

Comparație

Modificare preț

Ocugen Inc Așteptări

Obiectiv de preț

By TipRanks

732.37% sus

Prognoză pe 12 luni

Medie 11.57 USD 732.37%

Maxim 22 USD

Minim 7 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcugen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 7 analiști care au acordat evaluări ale acțiunilor Ocugen Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.6818 / 0.74Suport & Rezistență

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.